-
TransCode Therapeutics and Quantum Leap Advance TTX-MC138 Development with IND Amendment Submission for Phase 2a Trial
NASDAQ: $RNAZ A Significant Step Forward in Oncology Treatment TransCode Therapeutics, Inc. and Quantum Leap Healthcare Collaborative (QLHC) have jointly announced a noteworthy progression in their ongoing research and development efforts. The companies have officially submitted an Investigational New Drug (IND) amendment to the U.S. Food and Drug Administration (FDA). This submission pertains to the…
-
Decoy Therapeutics Highlights Global Access Commitment Following Investor Presentation
NASDAQ: $DCOY Decoy Therapeutics Showcases Commitment to Global Accessibility During Recent Investor Event Decoy Therapeutics, Inc. recently participated in a dedicated segment during a virtual investor conference, focusing a significant portion of its presentation on the implications and execution strategy of its recently announced Global Access Commitment Agreement. The company utilized this platform to elaborate…
-
Amgen’s 2025 Financial Performance: A Review of Fourth Quarter and Full-Year Results
NASDAQ: $AMGN Amgen recently announced its financial results for the fourth quarter and the full year ended December 31, 2025. The company’s performance reflects ongoing strategic initiatives and the impact of its evolving portfolio in the biotechnology sector. For the fourth quarter of 2025, Amgen reported total revenue of approximately $8.2 billion. This figure marks…
-
Rigel Strengthens Leadership with Appointment of Michael P. Miller to Board of Directors
NASDAQ: $RIGL Rigel Pharmaceuticals, Inc. recently announced a significant addition to its leadership structure with the appointment of Michael P. Miller to its Board of Directors, effective immediately. Mr. Miller brings a wealth of experience in the biotechnology and pharmaceutical sectors, promising to contribute valuable strategic insights as Rigel continues to advance its pipeline and…
-
Avidity Biosciences Sets Record Date for Potential Spin-Off of RNA Therapeutics Business
NASDAQ: $RNA Avidity Biosciences, Inc. has recently announced a significant corporate development concerning its RNA therapeutics business. The company has established an expected record date for the potential separation of its RNA therapeutics business into an independent, publicly traded entity. The Potential Spin-Off Explained In a move designed to potentially maximize shareholder value and allow…
-
ADC Therapeutics Strengthens Team with New Employee Inducement Grants
NYSE: $ADCT ADC Therapeutics SA, a commercial-stage, late-stage biotechnology company focused on the development and commercialization of antibody drug conjugates (ADCs) for patients suffering from cancer, recently announced a significant commitment to its growing workforce. In a filing dated December 17, 2024, the company disclosed the granting of equity awards to newly hired employees under…
-
Anixa Biosciences Advances CAR-T Therapy with U.S. Adopted Name Approval
NASDAQ: $ANIX Anixa Biosciences, Inc., a biotechnology company focused on the development of innovative cancer therapies, has reached a significant milestone in the progression of its CAR-T cell therapy candidate. The company announced that the United States Adopted Names (USAN) Council has approved the non-proprietary name for its novel CAR-T therapy. This approval of a…
-
PDS Biotech Secures New U.S. Patent for Core Technology
NASDAQ: $PDSB Pharmaceutical development is a meticulous and often lengthy process, where intellectual property protection is paramount to innovation. In a significant move for the sector, PDS Biotech recently announced the issuance of a new U.S. Patent. This patent specifically covers the fundamental technology platform that underpins one of the company’s key investigational products, PDS0.…
-
Clene’s Upcoming Presentation at the Emerging Growth Conference: What Investors Should Know
NASDAQ: $CLNN Clene Inc., a clinical-stage company focused on developing treatments that target neurodegeneration and inflammation, has announced its participation in a significant industry event. The company is scheduled to present at the Emerging Growth Conference, as detailed in their recent press release. The Significance of the Emerging Growth Conference The Emerging Growth Conference (EGC)…
-
Exciting Progress: Corvus Pharmaceuticals Poised to Share Promising Data on Soquelitinib for Atopic Dermatitis
NASDAQ: $CRVS Pharmaceutical research is a journey of meticulous steps, and today, the spotlight shines brightly on Corvus Pharmaceuticals as they prepare to share significant updates from their ongoing clinical investigations. Specifically, the market and the patient community are eagerly anticipating the forthcoming announcement regarding the results from Cohort 4 of the placebo-controlled Phase 1…